Tuesday, Dec 7, 2021

Tolebrutinib's Phase 2b Trial Shows Dose-Dependent MS Lession Reduction

August 26, 2021    Marco MeglioThe results support continued development of tolebrutinib 60 mg in phase 3 trials for MS, based on the..


 August 26, 2021    Marco Meglio

The results support continued development of tolebrutinib 60 mg in phase 3 trials for MS, based on the well-established relationship between reductions of Gadolinium-enhancing lesions and relapse rates.

figure image

Daniel Reich, MD, PhD

Treatment with tolebrutinib (Sanofi), an oral Bruton’s tyrosine kinase (BTK) inhibitor, demonstrated a dose-dependent reduction in the number of new gadolinium-enhancing (GdE) lesions and was well-tolerated among patients with relapsing-remitting multiple sclerosis (RRMS) or relapsing secondary progressive MS (SPMS) in a phase 2b study (NCT03889639).

Lead author Daniel Reich, MD, PhD, senior investigator, National Institutes of Neurological Disorders and Stroke, National Institutes of Health, and colleagues conducted a 16-week, double-blind, placebo-controlled, crossover, dose-finding trial that assigned 130 participants to tolebrutinib 5 mg (n = 33), 15 mg (n = 32), 30 mg (n = 33), and 60 mg (n = 32). Patients with RRMS and SMPS underwent MRI scans at screening and every 4 weeks over the 16-week stretch. Cohort 1 received the investigational drug for 12 weeks, then matched placebo for 4 weeks, whereas those in cohort 2 received4 weeks of placebo followed by 12 weeks of tolebrutinb.

An exponential model showed a dose-response relationship between tolebrutinib and new GdE lesions, which was used to reject the null hypothesis of a flat dose-response curve (test statistic, 2.47; = .03). The 60-mg dose was the most efficacious, with an observed mean number of lesions of 0.13 (standard deviation [SD], 0.43) compared to 1.03 (SD, 2.50) for placebo. Furthermore, 28 of the 31 participants (90%) who received the 60-mg dose had no new GdE lesions after 12 weeks of treatment, compared with 44 of 59 participants (75%) in cohort 2 placebo period observed at week 4.

"In summary our study design with short placebo exposure established an effect of tolebrutinib on MRI measures related to new lesion formation and identified a dose to test in phase 3 trials," Reich et al concluded. "Effective treatment for acute inflammation, combined with the potential to directly modulate the immune response within the CNS—known to be a key driver of clinical progression in multiple sclerosis—provides scientific rationale to pursue phase 3 clinical trials in patients with both relapsing and progressive forms of multiple sclerosis."

Each tolebrutinib group had similar occurrence of adverse events (AEs), none of which led to treatment or study discontinuation. Across doses, 1 serious AE was observed: a severe MS relapse in a participant who received 60-mg tolebrutinib in cohort 1. That patient did not have their study participation interrupted, and they recovered and completed the trial.




By: Stuart http://www.blogger.com/profile/[email protected]
Title: Tolebrutinib Shows Dose-Dependent MS Lesion Reduction in Phase 2b Trial
Sourced From: wwwmsviewsandrelatednews.blogspot.com/feeds/7177417774640972883/comments/default
Published Date: Sat, 28 Aug 2021 20:59:00 +0000

Read More
Did you miss our previous article...